Table 4.
Comparison of clinical manifestations of CAPS among Chinese patients, Japanese patients, and western patients
| Total | Japan | p1 value | Western | p2 value | |
|---|---|---|---|---|---|
| n | 42 | 19 | 136 | ||
| Origin | Chinese | Japanese | Most Caucasian | ||
| Gender Ratio | 26:16 | 11:8 | 0.767a | 69:67 | 0.205a |
| Fever | 41 (97.6%) | 14 (73.7%) | 0.009b | 108 (79%) | 0.005a |
| Rash | 39 (92.9%) | 19 (100%) | 0.545b | 132 (97%) | 0.358b |
| Ocular manifestations | 15 (35.7%) | 12 (63.2%) | 0.046a | 97 (71%) | < 0.001a |
| Hearing loss | 15 (35.7%) | 7 (36.8%) | 0.932a | 56 (41%) | 0.527a |
| Neurological symptoms | 21/35 (60%)† | NA | 55 (40%) | 0.038a | |
| Severe Neurological symptoms | 6/20 (30%)‡ | NA | 16 (12%) | 0.040b | |
| Musculoskeletal manifestations | 28 (66.7%) | 13 (68.4%) | 0.892a | 117 (86%) | 0.005a |
| Severe Musculoskeletal manifestations | 4/20 (20.0%)‡ | NA | 6 (4%) | 0.025b |
aCompared by Chi-square test, bCompared by Fisher exact test
†Reference [13] didn’t describe the CNS symptoms and thus 7 patients in their cohort were removed in the comparison of neurological symptoms
‡References [12, 13] didn’t describe the detailed manifestations of CNS and musculoskeletal system, and thus patients in their cohort (15 and 7, respectively) were removed when comparison was performed in terms of severe symptoms
p1 refers Chinese population versus Japanese population, p2 refers Chinese population versus western population